INmune Bio FY2024 net loss $42.1M; AD02 top-line data expected June 2025

Inmune Bio, Inc.

Net loss $42.1M vs $30.0M in FY2023; R&D expenses rose to $33.2M from $20.3M.
Cash and equivalents $20.9M as of Dec 31, 2024; $22.9M shares outstanding.
Completed $27.5M equity offering (incl. ~3.9M warrants) and repaid Silicon Valley Bank loan.
AD02 Phase 2 Alzheimer's trial fully enrolled (208 patients); top-line cognitive results due June 2025.
CORDStrom planning BLA filing in RDEB in 2025/early 2026, eligible for Priority Review Voucher.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.